Alpha 2.0
Login Register
» Authors » Guendalina Froechlich

Guendalina Froechlich

Explore the profile of Guendalina Froechlich including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 231
Followers 0
Related Specialties
Oncology
Science
Biochemistry
Top 10 Co-Authors
Emanuele Sasso
Nicola Zambrano
Alfredo Nicosia
Elisa Scarselli
Claudia De Lorenzo
Anna Morena DAlise
Margherita Passariello
Chiara Gentile
Gabriella Cotugno
Cinzia Vetrei
Published In
Cancers (Basel)
Sci Rep
MAbs
Int J Mol Sci
Biomed Res Int
Affiliations
Soon will be listed here.
Recent Articles
1.
Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors
Troise F, Leoni G, Sasso E, Del Sorbo M, Esposito M, Romano G, et al.
Mol Ther Oncol . 2024 Apr; 32(1):200760. PMID: 38596303
Neoantigen (neoAg)-based cancer vaccines expand preexisting antitumor immunity and elicit novel cancer-specific T cells. However, at odds with prophylactic vaccines, therapeutic antitumor immunity must be induced when the tumor is...
2.
The common H232 STING allele shows impaired activities in DNA sensing, susceptibility to viral infection, and in monocyte cell function, while the HAQ variant possesses wild-type properties
Froechlich G, Finizio A, Napolano A, Amiranda S, De Chiara A, Pagano P, et al.
Sci Rep . 2023 Nov; 13(1):19541. PMID: 37945588
Different innate immune pathways converge to Stimulator of interferon genes (STING) and trigger type I interferon responses after recognition of abnormal nucleic acids in the cells. This non-redundant function renders...
3.
New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
Rapuano Lembo R, Manna L, Froechlich G, Sasso E, Passariello M, De Lorenzo C
Cancers (Basel) . 2022 Nov; 14(21). PMID: 36358708
Antibody-based cancer immunotherapy includes monoclonals against immune checkpoints (ICs), to modulate specific T cell responses against cancer. NK cells are a newly emerging target for immune checkpoint receptor inhibition in...
4.
High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand
Zambrano N, Froechlich G, Lazarevic D, Passariello M, Nicosia A, De Lorenzo C, et al.
Cancers (Basel) . 2022 Mar; 14(5). PMID: 35267633
Monoclonal antibodies are among the most powerful therapeutics in modern medicine. Since the approval of the first therapeutic antibody in 1986, monoclonal antibodies keep holding great expectations for application in...
5.
Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC
Vetrei C, Passariello M, Froechlich G, Rapuano Lembo R, Sasso E, Zambrano N, et al.
Cancers (Basel) . 2022 Jan; 14(1). PMID: 35008285
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by a higher mortality rate among breast cancer subtypes. Poly(ADP-ribose) polymerase (PARP) inhibitors are used in clinics...
6.
Generation of a Retargeted Oncolytic Virus Encoding Adenosine Deaminase for Tumor Adenosine Clearance
Gentile C, Finizio A, Froechlich G, DAlise A, Cotugno G, Amiranda S, et al.
Int J Mol Sci . 2021 Dec; 22(24). PMID: 34948316
Background: Oncolytic viruses are immunotherapeutic agents that can be engineered to encode payloads of interest within the tumor microenvironment to enhance therapeutic efficacy. Their therapeutic potential could be limited by...
7.
Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
Vetrei C, Passariello M, Froechlich G, Rapuano Lembo R, Zambrano N, De Lorenzo C
Cancers (Basel) . 2021 Jul; 13(12). PMID: 34201082
Antibodies targeting Immune Checkpoints (IC) on tumor infiltrating lymphocytes improve immune responses against cancer. Recently, the expression of some ICs has also been reported on cancer cells. We used the...
8.
Generation of a Novel Mesothelin-Targeted Oncolytic Virus and Implemented Strategies for Manufacturing
Froechlich G, Gentile C, Infante L, Caiazza C, Pagano P, Scatigna S, et al.
Int J Mol Sci . 2021 Jan; 22(2). PMID: 33418877
Background: HER2-based retargeted viruses are in advanced phases of preclinical development of breast cancer models. Mesothelin (MSLN) is a cell-surface tumor antigen expressed in different subtypes of breast and non-breast...
9.
Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Oncolytic Virus
Froechlich G, Caiazza C, Gentile C, DAlise A, De Lucia M, Langone F, et al.
Cancers (Basel) . 2020 Nov; 12(11). PMID: 33213060
The dichotomic contribution of cancer cell lysis and tumor immunogenicity is considered essential for effective oncovirotherapy, suggesting that the innate antiviral immune response is a hurdle for efficacy of oncolytic...
10.
Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
De Lucia M, Cotugno G, Bignone V, Garzia I, Nocchi L, Langone F, et al.
Mol Ther Oncolytics . 2020 Nov; 19:253-264. PMID: 33209980
Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an...